Ireland· IE-PA-EU/1/16/1094/001
NINLARO 2.3 mg hard capsules
A ixazomib product containing ixazomib citrate, registered in Ireland by Takeda Pharma A/S.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Ixazomib citrate
- Manufacturer
- Takeda Pharma A/S
- Country
- Ireland (IE)
- ATC code
- L01XX50
- ATC class
- Ixazomib
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/16/1094/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
226 interactions on record for ixazomib.
Graded by severity as the source publishes them — 45 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ixazomib · interactions on record
226 records
- 45 severe
- 181 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- RifampicinJ04AB02severe
- RifabutinJ04AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ixazomib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomIxazomib 2.3mg capsulesTakeda UK Ltd
- United StatesNINLAROTakeda Pharmaceuticals America, Inc.
- SwitzerlandNinlaro 2.3 mg, HartkapselnTakeda Pharma AG
- CzechiaNINLAROTakeda Pharma A/S, Vallensbaek Strand
- SpainNINLARO 2,3 MG CAPSULAS DURASTakeda Pharma A/S
- FinlandNINLAROTakeda Pharma A/S
- FranceNINLARO 2,3 mg, géluleTAKEDA PHARMA (DANEMARK)
- CanadaNINLAROTAKEDA CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ninlaro
- Liechtenstein · Ninlaro
- Norway · Ninlaro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b83b4518-ce4e-4485-a228-314c6d11e5cd GET /v1/drugs/b83b4518-ce4e-4485-a228-314c6d11e5cd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, hard",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01XX",
"L01XX50"
],
"strength": null,
"pa_number": "EU/1/16/1094/001",
"substances": [
"Ixazomib citrate"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "21/11/2016",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about ixazomib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.